This week in charts: Biotech’s rebound is undeniable
Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.